Other Corporate Information – Page 11

2024-05-20

Alligator Bioscience Announces Publication Highlighting Potential of Next-Generation CD40 Agonists in Peer-Reviewed Medical Journal “Expert Opinion on Biological Therapy”

Next-generation CD40 agonists have opportunity to address key biological and medical needs in immuno-oncology Bispecific CD40-targeting anti ...

2024-05-14

Study conducted by Moores Cancer Center at University of California San Diego to evaluate safety and efficacy of mitazalimab injected intrat ...

2024-04-26

Regulatory

Orion selects lead antibodies from the second discovery program Collaboration aims to discover and develop new bispecific antibody cancer th ...

2024-04-18

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2024-04-09

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2024-04-08

1st Presentation supports dosing regimen for mitazalimab in combination with FOLFORINOX and improvement of antitumor response 2nd Presentati ...

2024-03-26

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the publication of a scientific article featuring its no ...

2024-03-212024-03-21

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2024-03-07

Initial interim data show favorable drug exposure and confirm ALG.APV-527 biological activity Early promising signs of clinical activity in ...